{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T01:41:55Z","timestamp":1718847715860},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s12029-023-01012-4","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T13:02:00Z","timestamp":1705496520000},"page":"749-758","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Value of Serum CYFRA\u00a021-1 and CK19-2G2 for Tumor  Aggressiveness and Overall Survival in Hepatitis C-Related Hepatocellular Carcinoma Among Egyptians: A Prospective Study"],"prefix":"10.1007","volume":"55","author":[{"given":"Mohamed Yousry","family":"Taher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab Mostafa","family":"Hassouna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer Shawky","family":"El-Hadidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar Sameh","family":"El-aassar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Fathy","family":"Bakosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"1012_CR1","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301\u201314. https:\/\/doi.org\/10.1016\/s0140-6736(18)30010-2.","journal-title":"Lancet"},{"issue":"12","key":"1012_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3(12):1683\u201391. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3055.","journal-title":"JAMA Oncol"},{"issue":"15","key":"1012_CR3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/nejmra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362. https:\/\/doi.org\/10.1056\/nejmra1713263.","journal-title":"N Engl J Med"},{"issue":"33","key":"1012_CR4","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.3748\/wjg.v11.i33.5193","volume":"11","author":"AR El-Zayadi","year":"2005","unstructured":"El-Zayadi AR, Badran HM, Barakat EM, Mel-D A, Shawky S, Mohamed MK, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol. 2005;11(33):5193\u20138. https:\/\/doi.org\/10.3748\/wjg.v11.i33.5193.","journal-title":"World J Gastroenterol"},{"key":"1012_CR5","doi-asserted-by":"publisher","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. European association for the study of the liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","DOI":"10.1016\/j.jhep.2018.03.019"},{"key":"1012_CR6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/hep.22704","volume":"49","author":"L Mishra","year":"2009","unstructured":"Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, et al. Liver stem cells and hepatocellular carcinoma. Hepatology. 2009;49:318\u201329. https:\/\/doi.org\/10.1002\/hep.22704.","journal-title":"Hepatology"},{"key":"1012_CR7","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jhep.2019.06.001","volume":"71","author":"J Calderaro","year":"2019","unstructured":"Calderaro J, Ziol M, Paradis V, Zucman-Rossi J. Molecular and histological correlations in liver cancer. J Hepatol. 2019;71:616\u201330. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.001.","journal-title":"J Hepatol"},{"issue":"1","key":"1012_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(82)90400-7","volume":"31","author":"R Moll","year":"1982","unstructured":"Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 1982;31(1):11\u201324. https:\/\/doi.org\/10.1016\/0092-8674(82)90400-7.","journal-title":"Cell"},{"key":"1012_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2019.09.001","volume":"72","author":"S Werner","year":"2020","unstructured":"Werner S, Keller L, Pantel K. Epithelial keratins: biology and implications as diagnostic markers for liquid biopsies. Mol Aspects Med. 2020;72:100817. https:\/\/doi.org\/10.1016\/j.mam.2019.09.001.","journal-title":"Mol Aspects Med"},{"issue":"2","key":"1012_CR10","first-page":"368","volume":"4","author":"J Jose","year":"2013","unstructured":"Jose J, Sunil P, Madhavan Nirmal R, Varghese SS. Cyfra 21\u20131: an Overview. Oral Max Path J. 2013;4(2):368\u201377.","journal-title":"Oral Max Path J"},{"issue":"6","key":"1012_CR11","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/1097-0142(20000915)89:6<1285::aid-cncr13>.0.co;2-g","volume":"89","author":"B Nakata","year":"2000","unstructured":"Nakata B, Ogawa Y, Ishikawa T, Ikeda K, Kato Y, Nishino H, et al. Serum CYFRA 21\u20131 is one of the most reliable tumor markers for breast carcinoma. Cancer. 2000;89(6):1285\u201390. https:\/\/doi.org\/10.1002\/1097-0142(20000915)89:6%3C1285::aid-cncr13%3E3.0.co;2-g.","journal-title":"Cancer"},{"key":"1012_CR12","doi-asserted-by":"publisher","first-page":"9444","DOI":"10.1038\/srep09444","volume":"5","author":"Y Xu","year":"2015","unstructured":"Xu Y, Xu L, Qiu M, Wang J, Zhou Q, Xu L, et al. Prognostic value of serum cytokeratin 19 fragments (Cyfra 21\u20131) in patients with non-small cell lung cancer. Sci Rep. 2015;5:9444. https:\/\/doi.org\/10.1038\/srep09444.","journal-title":"Sci Rep"},{"issue":"2","key":"1012_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057092","volume":"8","author":"Y Kong","year":"2013","unstructured":"Kong Y, Wang J, Liu W, Chen Q, Yang J, Wei W, et al. Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients. PLoS ONE. 2013;8(2):e57092. https:\/\/doi.org\/10.1371\/journal.pone.0057092.","journal-title":"PLoS ONE"},{"issue":"7","key":"1012_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101979","volume":"9","author":"J Gao","year":"2014","unstructured":"Gao J, Lv F, Li J, Wu Z, Qi J. Serum cytokeratin 19 fragment, CK19-2G2, as a newly identified biomarker for lung cancer. PLoS ONE. 2014;9(7):e101979. https:\/\/doi.org\/10.1371\/journal.pone.0101979.","journal-title":"PLoS ONE"},{"issue":"17","key":"1012_CR15","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.7150\/jca.44697","volume":"11","author":"JY Zhuo","year":"2020","unstructured":"Zhuo JY, Lu D, Tan WY, Zheng SS, Shen YQ, Xu X. CK19-positive hepatocellular carcinoma is a characteristic subtype. J Cancer. 2020;11(17):5069\u201377. https:\/\/doi.org\/10.7150\/jca.44697.","journal-title":"J Cancer"},{"key":"1012_CR16","doi-asserted-by":"publisher","first-page":"4751","DOI":"10.3748\/wjg.v18.i34.4751","volume":"18","author":"JI Lee","year":"2014","unstructured":"Lee JI, Lee JW, Kim JM, Kim JK, Chung HJ, Kim YS. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers. World J Gastroenterol. 2014;18:4751\u20137. https:\/\/doi.org\/10.3748\/wjg.v18.i34.4751.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"1012_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/gutjnl-2012-304351","volume":"63","author":"O Govaere","year":"2014","unstructured":"Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut. 2014;63(4):674\u201385. https:\/\/doi.org\/10.1136\/gutjnl-2012-304351.","journal-title":"Gut"},{"issue":"6","key":"1012_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1159\/000510522","volume":"9","author":"H Rhee","year":"2020","unstructured":"Rhee H, Kim H, Park YN. Clinico-radio-pathological and molecular features of hepatocellular carcinomas with keratin 19 expression. Liver Cancer. 2020;9(6):663\u201381. https:\/\/doi.org\/10.1159\/000510522.","journal-title":"Liver Cancer"},{"issue":"11","key":"1012_CR19","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/cam4.1211","volume":"6","author":"T Kawai","year":"2017","unstructured":"Kawai T, Yasuchika K, Ishii T, Katayama H, Yoshitoshi EY, Ogiso S, et al. Identification of keratin 19-positive cancer stem cells associating human hepatocellular carcinoma using CYFRA 21\u20131. Cancer Med. 2017;6(11):2531\u201340. https:\/\/doi.org\/10.1002\/cam4.1211.","journal-title":"Cancer Med"},{"issue":"4","key":"1012_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.4172\/2329-6771.1000178","volume":"5","author":"BI Carr","year":"2016","unstructured":"Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, et al. A liver index and its relationship to indices of HCC aggressiveness. J Integr Oncol. 2016;5(4):178. https:\/\/doi.org\/10.4172\/2329-6771.1000178.","journal-title":"J Integr Oncol"},{"issue":"10","key":"1012_CR21","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.3390\/cancers12102776","volume":"12","author":"GP Caviglia","year":"2020","unstructured":"Caviglia GP, Ciruolo M, Olivero A, Carucci P, Rolle E, Rosso C, et al. Prognostic role of serum cytokeratin-19 fragment (CYFRA 21\u20131) in patients with hepatocellular carcinoma. Cancers (Basel). 2020;12(10):2776. https:\/\/doi.org\/10.3390\/cancers12102776.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1012_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/00042737-200102000-00011","volume":"13","author":"T Nagai","year":"2001","unstructured":"Nagai T, Murota M, Nishioka M, Fujita J, Ohtsuki Y, Dohmoto K, et al. Elevation of cytokeratin 19 fragment in serum in patients with hepatoma: its clinical significance. Eur J Gastroenterol Hepatol. 2001;13(2):157\u201361. https:\/\/doi.org\/10.1097\/00042737-200102000-00011.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"1012_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00432-006-0098-4","volume":"32","author":"Y Li","year":"2006","unstructured":"Li Y, Tang ZY, Tian B, Ye SL, Qin LX, Xue Q, et al. Serum CYFRA 21\u20131 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients. J Cancer Res Clin Oncol. 2006;32(8):515\u201320. https:\/\/doi.org\/10.1007\/s00432-006-0098-4.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1012_CR24","doi-asserted-by":"publisher","unstructured":"Muralidharan K. On sample size determination. Math J Interdiscip Sci. 2014;3(1):55\u201364. https:\/\/doi.org\/10.15415\/mjis.2014.31005.","DOI":"10.15415\/mjis.2014.31005"},{"key":"1012_CR25","first-page":"1","volume":"17","author":"D Dutta","year":"2021","unstructured":"Dutta D. Relevance of Child Pugh scoring system as inclusion criteria in hepatocellular carcinoma management. Japanese J Gastro Hepato. 2021;17:1\u20133.","journal-title":"Japanese J Gastro Hepato"},{"issue":"3","key":"1012_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"1012_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajme.2016.02.006","volume":"53","author":"SA Ebied","year":"2017","unstructured":"Ebied SA, Abdel-Rehim WM, El-Benhawy SA, El-Gawish MA, Hassan MA, El-Settawy II. Serum CYFRA 21\u20131 in Egyptian women with breast cancer. Alexandria J Med. 2017;53:41\u20137. https:\/\/doi.org\/10.1016\/j.ajme.2016.02.006.","journal-title":"Alexandria J Med"},{"issue":"1","key":"1012_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3343\/alm.2023.43.1.82","volume":"43","author":"S Yoon","year":"2023","unstructured":"Yoon S, Lim YK, Kim HR, Lee MK, Kweon OJ. Establishment of reference intervals of cytokeratin 19 fragment antigen 21\u20131 in Korean adults. Ann Lab Med. 2023;43(1):82\u20135. https:\/\/doi.org\/10.3343\/alm.2023.43.1.82.","journal-title":"Ann Lab Med"},{"issue":"3","key":"1012_CR29","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00534-005-1069-x","volume":"13","author":"T Uenishi","year":"2006","unstructured":"Uenishi T, Yamazaki O, Yamamoto T, Hirohashi K, Tanaka H, Tanaka S, et al. Clinical significance of serum cytokeratin-19 fragment (CYFRA 21\u20131) in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2006;13(3):239\u201344. https:\/\/doi.org\/10.1007\/s00534-005-1069-x.","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"1","key":"1012_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12957-022-02632-z","volume":"20","author":"SD Qin","year":"2022","unstructured":"Qin SD, Zhang J, Qi YP, Zhong JH, Xiang BD. Individual and joint influence of cytokeratin 19 and microvascular invasion on the prognosis of patients with hepatocellular carcinoma after hepatectomy. World J Surg Oncol. 2022;20(1):209. https:\/\/doi.org\/10.1186\/s12957-022-02632-z.","journal-title":"World J Surg Oncol"},{"issue":"3","key":"1012_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1148\/radiol.2017162846","volume":"286","author":"SY Choi","year":"2018","unstructured":"Choi SY, Kim SH, Park CK, Min JH, Lee JE, Choi YH, et al. Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology. 2018;286(3):897\u2013908. https:\/\/doi.org\/10.1148\/radiol.2017162846.","journal-title":"Radiology"},{"key":"1012_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejrad.2019.01.036","volume":"113","author":"XX Hu","year":"2019","unstructured":"Hu XX, Wang WT, Yang L, Yang ZX, Liang HY, Ding Y, et al. MR features based on LI-RADS identify cytokeratin 19 status of hepatocellular carcinomas. Eur J Radiol. 2019;113:7\u201314. https:\/\/doi.org\/10.1016\/j.ejrad.2019.01.036.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1012_CR33","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1478-3231.2011.02640.x","volume":"32","author":"HT Jeong","year":"2012","unstructured":"Jeong HT, Kim MJ, Kim YE, Park YN, Choi GH, Choi JS. MRI features of hepatocellular carcinoma expressing progenitor cell markers. Liver Int. 2012;32(3):430\u201340. https:\/\/doi.org\/10.1111\/j.1478-3231.2011.02640.x.","journal-title":"Liver Int"},{"issue":"5","key":"1012_CR34","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/hep.24559","volume":"54","author":"H Kim","year":"2011","unstructured":"Kim H, Choi GH, Na DC, Ahn EY, Kim GI, Lee JE, et al. Human hepatocellular carcinomas with \u201cStemness\u201d-related marker expression: keratin 19 expression and a poor prognosis. Hepatology. 2011;54(5):1707\u201317. https:\/\/doi.org\/10.1002\/hep.24559.","journal-title":"Hepatology"},{"issue":"12","key":"1012_CR35","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/liv.14223","volume":"39","author":"PR Galle","year":"2019","unstructured":"Galle PR, Foerster F, Kudo M, Chan SL, Llovet JM, Qin S, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int. 2019;39(12):2214\u201329. https:\/\/doi.org\/10.1111\/liv.14223.","journal-title":"Liver Int"},{"issue":"1","key":"1012_CR36","doi-asserted-by":"publisher","first-page":"12870","DOI":"10.1038\/s41598-017-12834-1","volume":"7","author":"DS Bai","year":"2017","unstructured":"Bai DS, Zhang C, Chen P, Jin SJ, Jiang GQ. The prognostic correlation of AFP level at diagnosis with pathological grade, progression, and survival of patients with hepatocellular carcinoma. Sci Rep. 2017;7(1):12870. https:\/\/doi.org\/10.1038\/s41598-017-12834-1.","journal-title":"Sci Rep"},{"key":"1012_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cca.2015.06.027","volume":"448","author":"DW Sun","year":"2015","unstructured":"Sun DW, Zhang YY, Sun XD, Chen YG, Qiu W, Ji M, et al. Prognostic value of cytokeratin 19 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2015;448:161\u20139. https:\/\/doi.org\/10.1016\/j.cca.2015.06.027.","journal-title":"Clin Chim Acta"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-01012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-023-01012-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-023-01012-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T01:06:47Z","timestamp":1718845607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-023-01012-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1012"],"URL":"https:\/\/doi.org\/10.1007\/s12029-023-01012-4","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,17]]},"assertion":[{"value":"31 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study participants provided informed consent in compliance with good clinical practice recommendations and the principles of the Declaration of Helsinki. The Institutional Review Board at the Faculty of Medicine, Alexandria University, approved this study (approval number: 201535).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}